The future of pneumococcal disease prevention.

Authors: Rodgers GL,Klugman KP,
Address: Scientific Affairs, Vaccines, Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA. gail.rodgers@pfizer.com
Journal: Vaccine.

Publication: 2011 Sep 14;29 Suppl 3:C43-8. doi: 10.1016/j.vaccine.2011.07.047.

abstract

pneumococcal disease (PD) is The leading cause of vaccine preventable deaths in children <5 years of age worldwide, with most of the deaths occurring in the developing world. prevention of PD in children has been achieved by vaccination with pneumococcal conjugate vaccine (PCV), the basis for which is induction of a protective antibody response against the bacterial polysaccharide capsule. Conjugation of the polysaccharide capsule to a protein carrier enables the generation of an immunologic response to the vaccine in young children, leading to protection against infection. The heptavalent PCV, which contains 7 of the 93 known pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) was the first PCV available, licensed in the US in 2000 and subsequently in many countries worldwide, including Latin American and Caribbean countries. Since its introduction, PCV7 has been documented effective for reducing invasive PD mortality and burden, as well as that of pneumonia and otitis media. Additionally, PD caused by the vaccine serotypes has decreased in the unimmunized population due to herd immunity induced by PCV7. Despite this success, significant disease burden still exists globally due to serotypes not included in PCV7. Currently there are 2 new PCVs that have been approved for use in children, a 10-valent vaccine (includes PCV7 serotypes plus serotypes 1, 5 and 7F) and a 13-valent vaccine (includes PCV7 serotypes plus serotypes 1, 3, 5, 6A, 7F and 19A). The selection of new serotypes to be included was based on importance of these serotypes as causes of PD. An additional 15-valent vaccine (includes PCV 7 serotypes plus serotypes 1, 3, 5, 6A, 7F, 19A, 22F and 33F) is undergoing clinical trial testing. In view of the 93 serotypes that are currently known, it seems clear that vaccines with greater coverage, likely based on proteins common to all serotypes, will be needed in the future. Technical and regulatory challenges to the development and approval of newer PCVs include a need for licensing criteria of common protein vaccines, establishment of correlates of protection for disease manifestations other than invasive disease, comparative efficacy data, and clinical trial testing of concomitant immunization of higher valency PCVs with other vaccines.

Related Articles
Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2010
Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep. 2010 Dec 10; 59(RR-11):1-18.
Review Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
BMC Infect Dis. 2012
Review Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. BMC Infect Dis. 2012 Sep 7; 12:207. Epub 2012 Sep 7.
Pneumococcal conjugated vaccine: PHiD-CV.
Expert Rev Anti Infect Ther. 2...
Pneumococcal conjugated vaccine: PHiD-CV.
Dinleyici EC, Yargic ZA. Expert Rev Anti Infect Ther. 2009 Nov; 7(9):1063-74.
Review The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Vaccine. 2011
Review The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N, Micone P, Gentile A. Vaccine. 2011 Sep 14; 29 Suppl 3:C35-42.
Review Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Int J Infect Dis. 2010
Review Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Isaacman DJ, McIntosh ED, Reinert RR. Int J Infect Dis. 2010 Mar; 14(3):e197-209. Epub 2009 Aug 22.
Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage.
Infect Immun. 2012
Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage.
Prevaes SM, van Wamel WJ, de Vogel CP, Veenhoven RH, van Gils EJ, van Belkum A, Sanders EA, Bogaert D. Infect Immun. 2012 Jun; 80(6):2186-93. Epub 2012 Mar 26.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.